Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
The tyrosine kinase inhibitor STI571 is a novel promising class of anticancer drugs. We report a case of cutaneous adverse reactions to STI571 in a young woman with blast crisis of chronic myeloid leukemia. She had first typical acute generalized exanthematous pustulosis mimicking mercury rash and then urticarial eruption. We suggest that cell pathways mediated by some tyrosine kinases might be involved in the pathogenesis of these skin eruptions.
Brouard
M C
MC
Department of Dermatology, University Hospital, Geneva, Switzerland. mcvpb@hotmail.com
Prins
C
C
Mach-Pascual
S
S
Saurat
J H
JH
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005076:Exanthema / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases